Cost burden of hepatitis C virus treatment in commercially insured patients – PubMed

Objectives: The new direct-acting antivirals (DAAs), introduced at the end of 2013, are effective in treating chronic hepatitis C virus (HCV) infection, but they may represent a substantial financial burden on patients and health insurers. We examine the use and costs of HCV medications in a commercially insured population.

study design: retrospective cohort study.

Reading: How expensive is hepatitis c treatment cost off insurance

Methods: We used claims data from 3,091 people with HCV infection (2012-2015). Outcomes included HCV medication use, inflation-adjusted out-of-pocket (OOP) and health plan expenses, and predictors of receiving new DAAs.

See also: Best Cheap Health Insurance in Wisconsin 2022 – ValuePenguin

Findings: Cumulatively, 9% of members with an HCV diagnosis were treated with HCV medications in 2012 and this increased to 32% in 2015. Of 3,091, 589 received new DAAs and 80% (n=465) completed a 12-week treatment regimen. After the new DAAS became available, the average annual health plan spend on HCV medications increased from $2,869 to $16,504 per member diagnosed with HCV (relative change, 475%; 95% CI, 352%-598%) and operating expense expense increased from $41 to $94 (relative change, 131%; 95% ci, 15%-247%). age (between 50 and 64 years [adjusted odds ratio (aor), 2.13; 95% CI, 1.29-3.53] and ≥65 years [aor, 2.01; 95% CI, 1.14- 3.55] compared to being <30 years old) and having liver cirrhosis (aor, 3.34; 95% CI, 2.64-4.21) were positively associated with receiving new DAAs, and a diagnosis of substance abuse. alcohol (aor, 0.70; 95% ic, 0.53-0.92) was negatively associated with receiving new daas.

Conclusions: The proportion of a commercially insured population with HCV infection who was treated with HCV medications doubled within 2 years after the availability of new DAAs. Member expenses were kept low, while the health plan covered 99% of the cost of HCV medications. During our 2-year follow-up, we did not observe any financial benefit to the health plan from the cure of HCV infection from new DAAs.

See also: Health Insurance Portability and Accountability Act of 1996 (HIPAA) | CDC

Related Posts

How Roofing Insurance Claims Work: What Contractors Need to Know

How Roofing Insurance Claims Work: What Contractors Need to Know

Understanding how roofing insurance claims work will help your insurance restoration business succeed and grow. By knowing the ins and outs of insurance, you can ensure a…

4 reasons your insurance company can cancel your auto policy – MarketWatch

4 reasons your insurance company can cancel your auto policy – MarketWatch

Can they really cancel my policy without asking? Your insurance company can cancel your policy, but they must provide written notice before doing so. the amount of…

Best Cheap Health Insurance in Wisconsin 2022 – ValuePenguin

Best Cheap Health Insurance in Wisconsin 2022 – ValuePenguin

affordable health insurance is available in wisconsin through the state’s marketplace. Finding the best health insurance plan for you can be difficult, so to help you get…

Tesla Insurance Review: Costs and Coverage (2022)

Tesla Insurance Review: Costs and Coverage (2022)

car insurance for tesla models tends to be quite expensive with rates typically higher than the national average of $1730 per year for comprehensive coverage. A 2017…

How to read your life insurance policy | Insure.com

How to read your life insurance policy | Insure.com

A life insurance policy is a contract between an insurance company and an individual. there are a variety of policies, lots of riders, and many choices to…

The role of insurance providers in supporting treatment and management of hepatitis C patients | BMC Health Services Research | Full Text

The role of insurance providers in supporting treatment and management of hepatitis C patients | BMC Health Services Research | Full Text

hcv epidemiology Today, one of the most important global public health challenges is represented by the hepatitis C virus (HCV), which imposes a dramatically relevant burden in…